Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation

Affiliations

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
³ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Free article

Case Reports

Iman Abou Dalle et al. Am J Hematol. 2020 Feb.

Free article

. 2020 Feb;95(2):227-229.

doi: 10.1002/ajh.25610. Epub 2019 Aug 29.

¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
³ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

No abstract available

References

1. Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27(5):658-670.
1. Cheah JJC, Hahn CN, Hiwase DK, Scott HS, Brown AL. Myeloid neoplasms with germline DDX41 mutation. Int J Hematol. 2017;106(2):163-174.
1. Lewinsohn M, Brown AL, Weinel LM, et al. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood. 2016;127(8):1017-1023.
1. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
1. Negoro E, Radivoyevitch T, Polprasert C, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30(12):2405-2409.